STOK — Stoke Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.51bn
- $1.27bn
- $36.56m
- 77
- 27
- 88
- 71
Annual cashflow statement for Stoke Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -52.2 | -85.8 | -101 | -105 | -89 |
| Depreciation | |||||
| Non-Cash Items | 6.81 | 17.9 | 24.6 | 27.2 | 28.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.33 | 0.046 | 43 | -6.03 | -28.1 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -42.2 | -66.9 | -31.9 | -81.1 | -86.9 |
| Capital Expenditures | -1.05 | -1.2 | -3.96 | -1.62 | -0.203 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -75.2 | -41.9 | 108 | -107 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.05 | -76.4 | -45.9 | 106 | -107 |
| Financing Cash Flow Items | -0.485 | -0.002 | 45.3 | 52.1 | 8.96 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 108 | 1.28 | 46.4 | 53 | 131 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 64.8 | -142 | -31.3 | 77.9 | -63.2 |